Fused quinazoline derivatives useful as tyrosine kinase inhibitors

US7078409B2 · kind B2 · utility

Assignee

• BETA PHARMA, INC. · US

Inventors

• Don Zhang · Princeton, US
• Guojian Xie · Cheshire, US
• Charles Davis · Decatur, US
• Zhengzhuang Cheng · New Haven, US
• Hang Chen · Boulder, US
• Yinxiang Wang · Beijing, CN
• Mehrnaz Kamal · Shelton, US

Key dates

• Filing date: Mar 26, 2003
• Grant date: Jul 18, 2006
• Expiry date: Oct 22, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D497/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to a compound having the structurewherein A is a 7–18 membered ring that comprises 0 to 6 heteroatoms selected from O, S, and N; R1 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8alkyl, substituted or unsubstituted C2-8alkenyl, substituted or unsubstituted C2-8alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; m is an integer from 0 to 3; X is selected from the group consisting of NR2, CHR3, O, or S; wherein R2 and R3 are each individually H or C1-8alkyl; R is selected from the group consisting of unsubstituted aryl, and substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-(C1-3)alkyl, substituted or unsubstituted aryl-(C3-7)cycloalkyl, substituted or unsubstituted heteroaryl-(C1-3)alkyl, and substituted or unsubstituted heteroaryl-(C3-7)cycloalkyl; and pharmaceutically acceptable salts thereof; with the proviso that if A is a 7 or 8 membered ring, then R1 is selected from the group consisting of other than H, C1–C4 alkyl, (C1–C4 alkoxy)C1–C4 alkyl, C1–C4 alkanoyl, C1–C4 alkoxy or —S(O)x(C1–C4 alkyl) w…